Vertex Pharmaceuticals Inc. (VRTX)

180.08
NASDAQ : Health Technology
Prev Close 180.52
Day Low/High 179.34 / 182.00
52 Wk Low/High 136.50 / 186.44
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 255.56M
Market Cap 46.13B
EPS 1.10
P/E Ratio 113.53
Div & Yield N.A. (N.A)

Latest News

Vertex Completes Enrollment Of Two Phase 3 Studies Of VX-659 In Triple Combination With Tezacaftor And Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Completes Enrollment Of Two Phase 3 Studies Of VX-659 In Triple Combination With Tezacaftor And Ivacaftor For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that enrollment is complete for the two Phase 3 studies of the next-generation corrector VX-659 in triple combination with tezacaftor and ivacaftor in people with cystic fibrosis (CF) with...

Vertex Announces Reimbursement Agreement In Australia For ORKAMBI® (lumacaftor/ivacaftor) For People With Cystic Fibrosis Ages Six Years And Older With Two Copies Of The F508del Mutation

Vertex Announces Reimbursement Agreement In Australia For ORKAMBI® (lumacaftor/ivacaftor) For People With Cystic Fibrosis Ages Six Years And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals (Europe) Limited announces finalization of an agreement with the Australian Government that allows for reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages six and over with cystic fibrosis (CF) who have two copies of...

Vertex And Genomics Plc Establish Collaboration To Use Human Genetics And Data Science To Advance Discovery Of Precision Medicines

Vertex And Genomics Plc Establish Collaboration To Use Human Genetics And Data Science To Advance Discovery Of Precision Medicines

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance...

Vertex Appoints Ludovic Fenaux As Senior Vice President, International Commercial Operations

Vertex Appoints Ludovic Fenaux As Senior Vice President, International Commercial Operations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International Commercial Operations with responsibility for commercial activities outside of the U.

Vertex Receives A Positive PBAC Recommendation For Reimbursement Of ORKAMBI® (lumacaftor/ivacaftor) To Treat Australians Ages Six And Over With Cystic Fibrosis And Two Copies Of The F508del Mutation

Vertex Receives A Positive PBAC Recommendation For Reimbursement Of ORKAMBI® (lumacaftor/ivacaftor) To Treat Australians Ages Six And Over With Cystic Fibrosis And Two Copies Of The F508del Mutation

Vertex Pharmaceuticals (Europe) Limited announces that it has received the Pharmaceutical Benefits Advisory Committee's (PBAC) recommendation for ORKAMBI ® (lumacaftor/ivacaftor) to be listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for...

Today Was Very Mediocre in Terms of the Rally

For the first time in what seems like forever the tech stocks didn’t lead.

Vertex Awards Two College Students Full Scholarships To The University Of Massachusetts

Vertex Awards Two College Students Full Scholarships To The University Of Massachusetts

Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in science, technology, engineering, art or math (STEAM) at any University of Massachusetts campus.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Vertex Receives European CHMP Positive Opinion For SYMKEVI® (tezacaftor/ivacaftor) For People With Cystic Fibrosis Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Receives European CHMP Positive Opinion For SYMKEVI® (tezacaftor/ivacaftor) For People With Cystic Fibrosis Aged 12 And Older With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals (Europe) Limited, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for SYMKEVI ® (tezacaftor/ivacaftor) in a combination regimen with...

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Investors will soon turn their attention to Corporate America's outlook for 2019. Here are several stocks that are worth a look.

Vertex Reports Second-Quarter 2018 Financial Results

Vertex Reports Second-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2018 and reviewed recent progress with its approved and investigational medicines.

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

Vertex To Announce Second Quarter 2018 Financial Results On July 25

Vertex To Announce Second Quarter 2018 Financial Results On July 25

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close.

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Galapagos' new cystic fibrosis drug trial results were weaker than expected.

Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor And Ivacaftor) To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Certain Mutations In The CFTR Gene

Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor And Ivacaftor) To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Certain Mutations In The CFTR Gene

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada approved PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the...

Vertex's Paul Negulescu Awarded The Warren Alpert Foundation Prize For Pioneering Discoveries In Cystic Fibrosis

Vertex's Paul Negulescu Awarded The Warren Alpert Foundation Prize For Pioneering Discoveries In Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year's Warren Alpert Foundation Prize for "transformative discoveries in the fields of genetics,...

Vertex Opens Expanded Research Site In San Diego

Vertex Opens Expanded Research Site In San Diego

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego.

Vertex Announces Long-Term Access Agreement In Sweden For Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

Vertex Announces Long-Term Access Agreement In Sweden For Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI ® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will...

The Vertex Foundation And Employees Donate $1 Million Through Matching Gift Program

The Vertex Foundation And Employees Donate $1 Million Through Matching Gift Program

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company's new dollar-for-dollar matching gift program.

Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of CF

Vertex Data Presented At European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early And Long-Term Disease-Modifying Potential Of Treating The Underlying Cause Of CF

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 10 scientific abstracts from the company's portfolio of cystic fibrosis (CF) medicines are being presented at the 41 st European Cystic Fibrosis Conference taking place June 6-9, 2018, in...

Vertex To Present At The Goldman Sachs Healthcare Conference On June 13

Vertex To Present At The Goldman Sachs Healthcare Conference On June 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.

2 Trading Opportunities in Health Care

2 Trading Opportunities in Health Care

The potential of these setups on the weekly chart is rather good.

Vertex Awards $400,000 In Scholarships To People Living With Cystic Fibrosis And Their Immediate Family Members

Vertex Awards $400,000 In Scholarships To People Living With Cystic Fibrosis And Their Immediate Family Members

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.

Vertex Reports First-Quarter 2018 Financial Results

Vertex Reports First-Quarter 2018 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2018 and reviewed recent progress with its approved and investigational medicines.

VX-445 Phase 3 Clinical Trial Program Overview

VX-445 Phase 3 Clinical Trial Program Overview

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).

TheStreet Quant Rating: B (Buy)